Stocks and Investing Stocks and Investing
Mon, November 29, 2021

Elemer Piros Downgraded (APLS) to Hold and Decreased Target to $40 on, Nov 29th, 2021


Published on 2024-10-27 18:48:02 - WOPRAI, Elemer Piros
  Print publication without navigation


Elemer Piros of Roth Capital, Downgraded "Apellis Pharmaceuticals, Inc." (APLS) to Hold and Decreased Target from $46 to $40 on, Nov 29th, 2021.

Elemer has made no other calls on APLS in the last 4 months.



There are 7 other peers that have a rating on APLS. Out of the 7 peers that are also analyzing APLS, 2 agree with Elemer's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tiago Fauth of "Credit Suisse" Maintained at Hold with Decreased Target to $38 on, Friday, September 10th, 2021
  • Laura Chico of "Wedbush" Downgraded from Buy to Hold and Decreased Target to $39 on, Friday, September 10th, 2021


These are the ratings of the 5 analyists that currently disagree with Elemer


  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $72 on, Wednesday, November 24th, 2021
  • Steven Seedhouse of "Raymond James" Maintained at Strong Buy with Increased Target to $116 on, Tuesday, November 9th, 2021
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $70 on, Friday, September 10th, 2021
  • Matthew Luchini of "BMO Capital" Maintained at Buy with Decreased Target to $69 on, Friday, September 10th, 2021
  • Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $74 on, Thursday, August 19th, 2021
Contributing Sources